Conditions: HIV Infections
Keywords: HIV dementia High HIV DNA within CD14+ PBMCs treatment experienced
Allocation: NA | Intervention model: SINGLE_GROUP
Enrollment: 15
Healthy volunteers: no

Brief summary:
High levels of HIV infection within blood monocyte/macrophages (a type of white cells in the bloodstream) increases risk of dementia in HIV-infected individuals. Maraviroc (Selzentry) is a HIV medication that works by blocking the entry of HIV in cells including monocytes/macrophages that use a receptor called CCR5. The study hypothesis is that the addition of Maraviroc to a HIV antiretroviral regimen in HIV-infected individuals with high levels of HIV-infected monocyte/macrophages will lead to a decrease in the levels of infected monocyte/macrophages and to decrease in brain inflammation as studied by magnetic resonance spectroscopy (MRS, a form of MRI study).

Detailed description:

Arms:
arm 1: None

Interventions: intervention 1: maraviroc (Selzentry)
Intervention descriptions: intervention 1: dosage varies with other medications being taken; will follow package insert guidelines

Protocol document: